Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 20/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21333341 | 1.00 | ABL1 (0.61) | ABL1 | |
| SCHEMBL25666670 | 0.81 | ALDH1A1 (0.42) | ABL1 | |
| SCHEMBL10171009 | 0.79 | ALDH1A1 (0.41) | ABL1 | |
| SCHEMBL21333467 | 0.78 | ABL1 (0.69) | ABL1 | |
| SCHEMBL30437624 | 0.78 | ABL1 (0.69) | ABL1 | |
| SCHEMBL21333753 | 0.76 | ABL1 (0.66) | ABL1 | |
| SCHEMBL23191196 | 0.76 | ABL1 (0.66) | ABL1 | |
| SCHEMBL21346030 | 0.76 | ABL1 (1.00) | ABL1 | |
| SCHEMBL23191241 | 0.76 | ABL1 (0.69) | ABL1 | |
| SCHEMBL21345286 | 0.75 | ABL1 (0.61) | ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340521-A1 | C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2025-11-06 | — | — | US | disclosed |
| US-12435047-B2 | c-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-10-07 | — | — | US | disclosed |
| US-20230303501-A1 | C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2023-09-28 | — | — | US | disclosed |
| US-11649218-B2 | C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435047-B2 | c-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same | ABL1, ABL2, MUSK | ABL1 1/4885 |
| US-20230303501-A1 | C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | ABL1, ABL2, MUSK | ABL1 1/4885 |
| US-11649218-B2 | C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same | ABL1, ABL2, MUSK | ABL1 1/4885 |
| US-20250340521-A1 | C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | ABL1, ABL2, MUSK | ABL1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.